top of page


Spencer C and Fatemi S. Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Practice and Research Clinical Endocrinology & Metabolism. 27(5): 701-12, 2013.  PMID: 24094640

Spencer CA, LoPresti JS and Fatemi S.. How Sensitive (Second-Generation) Thyroglobulin (Tg) Measurement is Changing Paradigms for Monitoring Patients with Differentiated Thyroid Cancer (DTC), in the Absence or Presence of Tg Autoantibodies (TgAb). Current Opinion in Endocrinology and Diabetes 21(5):394-404, 2014.  

PMID: 25122493 PMCID: PMC4154792

Spencer CA. Clinical Review: Clinical Utility of Thyroglobulin antibody (TgAb) measurements for patients with Differentiated Thyroid Cancers (DTC). JCEM 96(12): 3615-27, 2011. 

PMID: 21917876

Spencer CA, Petrovic I, Fatemi S and LoPresti JS. Serum Thyroglobulin (Tg) Monitoring of Patients with Differentiated Thyroid Cancer using Sensitive (Second-Generation) Immunometric assays (Tg2GIMA) can be disrupted by False-Negative and False-Positive Serum Thyroglobulin Autoantibody (TgAb). JCEM 99(12):4589, 2014. PMID: 25226290 PMCID: PMC4297889

Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.

JCEM 96(5): 1283-91, 2011.  PMID: 21325460

bottom of page